Table 6, CADTH Common Drug Review Analysis for Anticoagulation Clinic Versus GP Clinic Distribution Scenarios for VKA Monitoring (Three and Six months of Total Treatment Duration) - Rivaroxaban (Xarelto)

Scenario	Cost/Savings (3 Months)	Cost/Savings (6 Months)
95% GP versus 5% clinic (base case)	−$249	−$113
90% GP versus 10% clinic	−$238	−$98
80% GP versus 20% clinic	−$217	−$68
70% GP versus 30% clinic	−$195	−$39
60% GP versus 40% clinic	−$174	−$9
50% GP versus 50% clinic	−$152	$21

From: APPENDIX 1, CADTH COMMON DRUG REVIEW ANALYSES

Rivaroxaban (Xarelto): Treatment of Venous Thromboembolic Events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and Prevention of Recurrent DVT and PE [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 6CADTH Common Drug Review Analysis for Anticoagulation Clinic Versus GP Clinic Distribution Scenarios for VKA Monitoring (Three and Six months of Total Treatment Duration)